Published in Respir Res on May 25, 2006
A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis (2013) 1.18
Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res (2012) 1.08
Role of angiogenesis and vascular remodeling in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2007) 1.06
Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis. Proc Natl Acad Sci U S A (2010) 1.03
Angiogenesis in chronic lung disease. Chest (2007) 1.03
Spontaneous lung dysfunction and fibrosis in mice lacking connexin 40 and endothelial cell connexin 43. Am J Pathol (2011) 0.92
Serum inter-alpha-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury. Am J Respir Crit Care Med (2008) 0.92
Expression of hypoxia-inducible factor (HIF)-1a-vascular endothelial growth factor (VEGF)-inhibitory growth factor (ING)-4- axis in sarcoidosis patients. BMC Res Notes (2012) 0.87
Down-regulation of the inhibitor of growth family member 4 (ING4) in different forms of pulmonary fibrosis. Respir Res (2009) 0.85
Vascular remodelling in the pathogenesis of idiopathic pulmonary fibrosis. QJM (2014) 0.80
Angiogenic activity of sera from interstitial lung disease patients in relation to pulmonary function. Eur J Med Res (2010) 0.78
Angiogenic activity of sera from interstitial lung disease patients in relation to clinical and radiological changes. Eur J Med Res (2009) 0.78
Altered miRNA expression in pulmonary sarcoidosis. BMC Med Genet (2016) 0.77
Angiogenic activity of sera from extrinsic allergic alveolitis patients in relation to clinical, radiological, and functional pulmonary changes. Lung (2010) 0.77
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med (1998) 12.80
Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest (2004) 7.91
Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest (2004) 5.97
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev (2005) 4.65
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol (1994) 2.66
Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax (2004) 2.45
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42
The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol (1997) 2.41
Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2004) 2.35
Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest (2004) 2.10
Regulation of telomerase activity in rat lung fibroblasts. Am J Respir Cell Mol Biol (2002) 2.07
Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am J Respir Cell Mol Biol (2004) 2.06
PRECAPILLARY SYSTEMIC-PULMONARY ANASTOMOSES. Thorax (1963) 2.02
CXC chemokines in angiogenesis. Cytokine Growth Factor Rev (2005) 2.00
Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med (2003) 1.97
Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol (1999) 1.90
IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol (1999) 1.87
Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2004) 1.62
Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest (2005) 1.61
Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol (1998) 1.56
ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J (2002) 1.52
Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest (2005) 1.49
Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J (1998) 1.49
Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene (2003) 1.48
Interferons and their application in the diseases of the lung. Chest (2003) 1.45
CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med (2004) 1.40
Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. Am J Respir Crit Care Med (2002) 1.39
Interstitial lung diseases: an epidemiological overview. Eur Respir J Suppl (2001) 1.32
Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases. J Allergy Clin Immunol (2001) 1.30
In the human fetus, vascular endothelial growth factor is expressed in epithelial cells and myocytes, but not vascular endothelium: implications for mode of action. J Clin Endocrinol Metab (1994) 1.28
Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med (2002) 1.27
Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol (2005) 1.27
Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease. J Lab Clin Med (2000) 1.24
Oxygen-regulated transcription factors and their role in pulmonary disease. Respir Res (2000) 1.21
CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann N Y Acad Sci (2004) 1.18
TNF-alpha sensitizes normal and fibrotic human lung fibroblasts to Fas-induced apoptosis. Am J Respir Cell Mol Biol (2005) 1.17
ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2001) 1.14
Association of malignancy with diseases causing interstitial pulmonary changes. Chest (2002) 1.14
Overview of pulmonary fibrosis. Chest (2002) 1.13
Neoformation of blood vessels in association with rat lung fibrosis induced by bleomycin. Anat Rec (1994) 1.13
Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. Biochem Biophys Res Commun (2003) 1.12
CXC chemokines in angiogenesis related to pulmonary fibrosis. Chest (2002) 1.11
Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med (2005) 1.11
Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis. Am J Respir Crit Care Med (2005) 1.10
Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. Am J Physiol Heart Circ Physiol (2004) 1.06
Masters of angiogenesis. Nat Med (2005) 1.06
Apoptosis in lung pathophysiology. Am J Physiol Lung Cell Mol Physiol (2000) 1.05
Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc (2002) 1.00
Involvement of hypoxia-inducible factor 1 in pulmonary pathophysiology. Chest (2005) 1.00
Regulation of vascular development by fibroblast growth factors. Cell Tissue Res (2003) 0.99
Idiopathic pulmonary fibrosis. New insights into classification and pathogenesis usher in a new era therapeutic approaches. Am J Respir Cell Mol Biol (2003) 0.98
International consensus statement on idiopathic pulmonary fibrosis. Eur Respir J (2001) 0.96
Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis. Lung (2003) 0.96
Alveolar-capillary membrane in idiopathic interstitial pulmonary fibrosis. Electron microscopic study of 14 cases. Am Rev Respir Dis (1968) 0.94
Does idiopathic pulmonary fibrosis increase lung cancer risk? Am J Respir Crit Care Med (2000) 0.93
Idiopathic pulmonary fibrosis and malignancy. Curr Opin Pulm Med (2001) 0.93
Comparison of BALF concentrations of ENA-78 and IP10 in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Respir Med (2005) 0.93
Demystifying idiopathic interstitial pneumonia. Arch Intern Med (2003) 0.92
Angiogenesis and pulmonary fibrosis: feast or famine? Am J Respir Crit Care Med (2004) 0.92
Other smoking-affected pulmonary diseases. Clin Chest Med (2000) 0.92
Accumulation of CXCR3-expressing eosinophils and increased concentration of its ligands (IP10 and Mig) in bronchoalveolar lavage fluid of patients with chronic eosinophilic pneumonia. Int Arch Allergy Immunol (2005) 0.92
Neovascularization in idiopathic pulmonary fibrosis: too much or too little? Am J Respir Crit Care Med (2004) 0.91
Cancer and interstitial lung disease. Curr Opin Pulm Med (2004) 0.90
MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. J Cell Mol Med (2002) 0.90
VEGF and bFGF are highly expressed in intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia. J Pathol (2002) 0.89
Serum biomarkers in interstitial lung diseases. Respir Res (2005) 0.85
Th1/Th2 cytokine pattern in bronchoalveolar lavage fluid and induced sputum in pulmonary sarcoidosis. BMC Pulm Med (2005) 0.84
Analysis of EPC-1 growth state-dependent expression, specificity, and conservation of related sequences. J Cell Physiol (1995) 0.82
Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res (2001) 0.81
Application of microarray technology in pulmonary diseases. Respir Res (2004) 0.80
Cancer in interstitial pulmonary fibrosis and sarcoidosis. Curr Opin Pulm Med (2003) 0.80
Intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia are highly capillarized. Hum Pathol (1999) 0.79
Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). Sarcoidosis Vasc Diffuse Lung Dis (2004) 0.78
Current classification of idiopathic interstitial pneumonias. Monaldi Arch Chest Dis (2000) 0.78
Fine structural morphometry on biopsy specimens of human lung. 2. Diffuse idiopathic pulmonary fibrosis. Chest (1974) 0.77
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Pleural effusions in hematologic malignancies. Chest (2004) 3.14
Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.02
Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. Am J Respir Crit Care Med (2007) 1.67
Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2009) 1.51
Prevention of nosocomial maxillary sinusitis in the ICU: the effects of topically applied alpha-adrenergic agonists and corticosteroids. Intensive Care Med (2006) 1.48
Interferons and their application in the diseases of the lung. Chest (2003) 1.45
Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest (2005) 1.39
A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med (2013) 1.21
Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome. Sleep (2009) 1.21
Video-assisted thoracoscopic surgery for thoracic empyema: primarily, or after fibrinolytic therapy failure? Am J Surg (2004) 1.17
Fat embolism syndrome: clinical examination is still the preferable diagnostic method. Chest (2003) 1.15
Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest (2007) 1.14
Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol (2012) 1.13
The effect of obesity on pulmonary lung function of school aged children in Greece. Pediatr Pulmonol (2009) 1.10
Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? Am J Respir Crit Care Med (2013) 1.09
The predictive role of serum and bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress syndrome development and outcome. Respir Res (2002) 1.08
Obstructive sleep apnea aggravates glycemic control across the continuum of glucose homeostasis. Am J Respir Crit Care Med (2010) 1.08
COPD and IPF: it's all about regulation and balance. Thorax (2014) 1.07
Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. J Transl Med (2011) 1.07
Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests. Eur J Intern Med (2005) 1.06
A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect (2009) 1.05
Acute fibrinous and organising pneumonia: a case report and review of the literature. J Med Case Rep (2009) 1.05
The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J (2012) 1.03
Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest (2006) 1.02
Smoking acutely increases plasma ghrelin concentrations. Clin Chem (2006) 1.01
γ-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer. Onco Targets Ther (2012) 1.00
Inflammatory markers in middle-aged obese subjects: does obstructive sleep apnea syndrome play a role? Mediators Inflamm (2010) 0.98
Prognostic value of serum tumor markers in patients with lung cancer. Respiration (2002) 0.96
Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema. BMC Pulm Med (2013) 0.96
Pleural effusions in critically ill patients. Respiration (2008) 0.95
Induced sputum CD8+ T-lymphocyte subpopulations in chronic obstructive pulmonary disease. Respir Med (2004) 0.95
Community acquired bacterial pneumonia. Expert Opin Pharmacother (2010) 0.95
Involvement of lymphatic metastatic spread in non-small cell lung cancer accordingly to the primary cancer location. Lung Cancer (2004) 0.94
The relationships among hydrogen peroxide in expired breath condensate, airway inflammation, and asthma severity. Chest (2002) 0.94
Intrapleural streptokinase for pleural infection. BMJ (2006) 0.94
HbA1c is associated with severity of obstructive sleep apnea hypopnea syndrome in nondiabetic men. Vasc Health Risk Manag (2009) 0.93
Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. J Interferon Cytokine Res (2006) 0.92
Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther (2006) 0.92
Lung cancer and interstitial lung diseases: a systematic review. Pulm Med (2012) 0.92
The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Respiratory Distress Syndrome. BMC Pulm Med (2004) 0.92
Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med (2012) 0.92
Exhaled H(2)O(2) in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease. Chest (2002) 0.91
Combined pulmonary fibrosis and emphysema. Expert Rev Respir Med (2013) 0.91
Stem cell therapy in pulmonary fibrosis. Curr Opin Pulm Med (2011) 0.91
Markers of glycemic control and insulin resistance in non-diabetic patients with Obstructive Sleep Apnea Hypopnea Syndrome: does adherence to CPAP treatment improve glycemic control? Sleep Med (2009) 0.91
Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration (2011) 0.90
Comorbidities and chronic obstructive pulmonary disease: is there a place for lung fibrosis? Am J Respir Crit Care Med (2013) 0.90
Sleepiness as a marker of glucose deregulation in obstructive sleep apnea. Sleep Breath (2011) 0.89
Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2008) 0.89
The cost of COPD exacerbations: a university hospital--based study in Greece. Respir Med (2011) 0.89
Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis. Curr Top Med Chem (2016) 0.89
Recombinant tissue plasminogen activator in the treatment of pleural infections in adults. Respir Med (2008) 0.88
Clinical features of lung cancer in patients with connective tissue diseases: a 10-year hospital based study. Respir Med (2008) 0.88
Continuous positive airway pressure treatment in patients with sleep apnoea: does it really improve glucose metabolism? Curr Diabetes Rev (2010) 0.88
Lower respiratory tract infections caused by Haemophilus influenzae: clinical features and predictors of outcome. Med Sci Monit (2009) 0.87
Sleep apnea syndrome and diastolic blood pressure elevation during exercise. Respiration (2004) 0.87
Expression of hypoxia-inducible factor (HIF)-1a-vascular endothelial growth factor (VEGF)-inhibitory growth factor (ING)-4- axis in sarcoidosis patients. BMC Res Notes (2012) 0.87
Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J (2002) 0.87
Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. Cancer (2008) 0.87
Stem cell treatment for chronic lung diseases. Respiration (2013) 0.87
Prevalence and clinical characteristics of obesity hypoventilation syndrome among individuals reporting sleep-related breathing symptoms in northern Greece. Sleep Breath (2010) 0.86
Sleep-disordered breathing and quality of life of railway drivers in Greece. Chest (2008) 0.86
Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis. Respir Med (2007) 0.86
Stem cell therapy in chronic obstructive pulmonary disease. Seeking the Prometheus effect. Curr Drug Targets (2013) 0.86
Current evidence for the management of paediatric parapneumonic effusions. Curr Med Res Opin (2012) 0.86
Combined pulmonary fibrosis and emphysema associated with microscopic polyangiitis. Eur Respir J (2012) 0.85
Serum biomarkers in interstitial lung diseases. Respir Res (2005) 0.85
Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis. Biomed Res Int (2013) 0.85
Serum biomarkers in acute respiratory distress syndrome an ailing prognosticator. Respir Res (2005) 0.85
Down-regulation of the inhibitor of growth family member 4 (ING4) in different forms of pulmonary fibrosis. Respir Res (2009) 0.85
Diagnostic value of interleukin-1alpha, interleukin-6, and tumor necrosis factor in pleural effusions. Chest (2002) 0.84
Th1/Th2 cytokine pattern in bronchoalveolar lavage fluid and induced sputum in pulmonary sarcoidosis. BMC Pulm Med (2005) 0.84
Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway. Cancer Lett (2008) 0.84
Current pharmacological treatment of pulmonary arterial hypertension. Curr Clin Pharmacol (2008) 0.83
A trial of intrapleural streptokinase. N Engl J Med (2005) 0.83
Autophagy and Bcl-2/BNIP3 death regulatory pathway in non-small cell lung carcinomas. APMIS (2012) 0.82
Predictors of obstructive sleep apnea in males with metabolic syndrome. Vasc Health Risk Manag (2010) 0.82
Autoimmunity and chronic obstructive pulmonary disease: thinking beyond cigarette smoke. Am J Respir Crit Care Med (2012) 0.82
Determinants of continuous positive airway pressure compliance in a group of Greek patients with obstructive sleep apnea. Eur J Intern Med (2009) 0.82
8-Isoprostane, a marker of oxidative stress, is increased in the expired breath condensate of patients with pulmonary sarcoidosis. Chest (2004) 0.82
Quality of life in patients with active sarcoidosis in Greece. Eur J Intern Med (2006) 0.82
Decreased apoptotic rate of alveolar macrophages of patients with idiopathic pulmonary fibrosis. Pulm Med (2012) 0.82
E-cadherin expression on fine-needle aspiration biopsies in primary lung adenocarcinomas is related to tumor differentiation and invasion. Anticancer Res (2003) 0.81
Steep barriers to overcome for successful application of stem cell treatment in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2013) 0.81
Continuous positive airways pressure treatment in a patient with sleep apnea-hypopnea syndrome and coexisting bipolar disorder. Psychopharmacol Bull (2008) 0.81
Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC). Anticancer Res (2008) 0.80
Serologic evaluation in idiopathic interstitial pneumonias. Curr Opin Pulm Med (2012) 0.80
Mechanisms of pleural involvement in orphan diseases. Respiration (2012) 0.80
Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients. Lung (2014) 0.80
Application of microarray technology in pulmonary diseases. Respir Res (2004) 0.80
Plasma visfatin levels in severe obstructive sleep apnea-hypopnea syndrome. Sleep Breath (2009) 0.80
Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays. Cancer Inform (2007) 0.80